Maxim Group Upgrades Cellectar Biosciences (CLRB)

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks CLRB Maxim Group Upgrades Cellectar Biosciences (CLRB) March 10, 2026 — 08:03 pm EDT Written by George Maybach for Fintel-> Fintel reports that on March 10, 2026, Maxim Group upgraded their outlook for Cellectar Biosciences (NasdaqCM:CLRB) from Hold to Buy.

Analyst Price Forecast Suggests 1,456.49% Upside As of February 25, 2026, the average one-year price target for Cellectar Biosciences is $47.94/share. The forecasts range from a low of $18.18 to a high of $79.80. The average price target represents an increase of 1,456.49% from its latest reported closing price of $3.08 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Cellectar Biosciences is 97MM. The projected annual non-GAAP EPS is -3.68. What is the Fund Sentiment? There are 27 funds or institutions reporting positions in Cellectar Biosciences. This is an decrease of 9 owner(s) or 25.00% in the last quarter. Average portfolio weight of all funds dedicated to CLRB is 0.00%, an increase of 25.70%. Total shares owned by institutions decreased in the last three months by 45.64% to 351K shares. What are Other Shareholders Doing? Bleichroeder holds 100K shares representing 2.36% ownership of the company. No change in the last quarter. DRW Securities holds 45K shares representing 1.07% ownership of the company. In its prior filing, the firm reported owning 21K shares , representing an increase of 53.31%. The firm increased its portfolio allocation in CLRB by 62.74% over the last quarter.

Geode Capital Management holds 29K shares representing 0.68% ownership of the company. In its prior filing, the firm reported owning 25K shares , representing an increase of 13.07%. The firm decreased its portfolio allocation in CLRB by 41.38% over the last quarter.

Sequoia Financial Advisors holds 25K shares representing 0.60% ownership of the company. In its prior filing, the firm reported owning 11K shares , representing an increase of 57.46%. The firm increased its portfolio allocation in CLRB by 13.67% over the last quarter.

Warberg Asset Management holds 14K shares representing 0.33% ownership of the company. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Cellectar Biosciences, Inc.-> Find out what the Options Markets think of Cellectar Biosciences, Inc.-> See our take on Cellectar Biosciences, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned CLRB More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.